United States · FDA National Drug Code directory
Bivalirudin
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 63323-562_c6dcd639-86b8-40e0-b18b-e2d4393f274b
- Product NDC
- 63323-562
- Form
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Composition / generic term
- Bivalirudin
- Labeler
- Fresenius Kabi USA, LLC
- Marketing category
- ANDA
- Marketing start / end (source format)
- 20171030
- Source listing expiry
- 20261231
Source-listed ingredients
- BIVALIRUDIN — 250 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 10 VIAL, SINGLE-USE in 1 CARTON (63323-562-15) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-USE (63323-562-41) · 63323-562-15
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →